Abstract
The beta hemolytic streptococcus group B (GBS) emerged as a major pathologic threat to infants in the 1960s and continues to be the leading cause of maternal and neonatal morbidity in the 1990s. Current approaches to prevention are directed toward eliminating exposure to the pathogen through chemoprophylaxis or enhancing host resistance through immunoprophylaxis. Because research is advancing rapidly in this area, perinatal nurses should keep abreast of changes in prevention and treatment strategies to enhance patient education and improve care.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call